The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Thomas, J. S.
Hanby, A. M.
van Tienhoven, G.
Cameron, D. A.
Bartlett, J. M. S.
Kunkler, I. H.
Funding for this research was provided by:
Medical Research Council (EME 09/800/31)
unspecified valid from 2017-02-11